Connor A. Tsuchida

Connor A. Tsuchida

Auto-generated profile, based on publicly available information

Connor A. Tsuchida

University of California, Berkeley—University of California, San Francisco Graduate Program in Bioengineering, University of California, Berkeley, CA 94720

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2020 in Science
Verified
Journal Article
Closed access
PPPatrick Pausch
Patrick Pausch
BABasem Al-Shayeb
Basem Al-Shayeb
EBEzra Bisom-Rapp
Ezra Bisom-Rapp
CTConnor A. Tsuchida
Connor A. Tsuchida
ZLZheng Li
Zheng Li
JDJennifer A. Doudna
Jennifer A. Doudna
Compact defense system in bacteriophages: The CRISPR-Cas system, naturally found in many prokaryotes, is widely used for genome editing. CRISPR arrays in the bacterial genome, derived from the genome of invading viruses, are used to generate a CRISPR RNA that guides the Cas enzyme to destroy repeat viral invaders. Recently, an unexpectedly compact CRISPR-Cas system was identified in huge bacteriophages. Pausch et al . show that even though this system lacks commonly found accessory proteins, it is functional. In addition to a CRISPR array, the only component of the system is an enzyme called CasF, which uses the same active site to process transcripts of the CRISPR arrays into CRISPR RNA and to destroy foreign nucleic acids. This system, which is active in human and plant cells, provides a hypercompact addition to the genome-editing toolbox. Science this issue p. 333

1 June 2021 in Cell Reports
Verified
Journal Article
Open access
JHJennifer R. Hamilton
Jennifer R. Hamilton
CTConnor A. Tsuchida
Connor A. Tsuchida
DNDavid N. Nguyen
David N. Nguyen
BSBrian R. Shy
Brian R. Shy
EME. Riley McGarrigle
E. Riley McGarrigle
JDJennifer A. Doudna
Jennifer A. Doudna
As genome engineering advances cell-based therapies, a versatile approach to introducing both CRISPR-Cas9 ribonucleoproteins (RNPs) and therapeutic transgenes into specific cells would be transformative. Autologous T cells expressing a chimeric antigen receptor (CAR) manufactured by viral transduction are approved to treat multiple blood cancers, but additional genetic modifications to alter cell programs will likely be required to treat solid tumors and for allogeneic cellular therapies. We have developed a one-step strategy using engineered lentiviral particles to introduce Cas9 RNPs and a CAR transgene into primary human T cells without electroporation. Furthermore, programming particle tropism allows us to target a specific cell type within a mixed cell population. As a proof-of-concept, we show that HIV-1 envelope targeted particles to edit CD4+ cells while sparing co-cultured CD8+ cells. This adaptable approach to immune cell engineering ex vivo provides a strategy applicable to the genetic modification of targeted somatic cells in vivo.

1 June 2018 in Neoplasia
Verified
Journal Article
Open access
CMChris P. Miller
Chris P. Miller
CTConnor Tsuchida
Connor Tsuchida
YZYing Zheng
Ying Zheng
JHJonathan Himmelfarb
Jonathan Himmelfarb
SAShreeram Akilesh
Shreeram Akilesh
Tractable human tissue-engineered 3D models of cancer that enable fine control of tumor growth, metabolism, and reciprocal interactions between different cell types in the tumor microenvironment promise to accelerate cancer research and pharmacologic testing. Progress to date mostly reflects the use of immortalized cancer cell lines, and progression to primary patient-derived tumor cells is needed to realize the full potential of these platforms. For the first time, we report endothelial sprouting induced by primary patient tumor cells in a 3D microfluidic system. Specifically, we have combined primary human clear cell renal cell carcinoma (ccRCC) cells from six independent donors with human endothelial cells in a vascularized, flow-directed, 3D culture system ("ccRCC-on-a-chip"). The upregulation of key angiogenic factors in primary human ccRCC cells, which exhibited unique patterns of donor variation, was further enhanced when they were cultured in 3D clusters. When embedded in the matrix surrounding engineered human vessels, these ccRCC tumor clusters drove potent endothelial cell sprouting under continuous flow, thus recapitulating the critical angiogenic signaling axis between human ccRCC cells and endothelial cells. Importantly, this phenotype was driven by a primary tumor cell-derived biochemical gradient of angiogenic growth factor accumulation that was subject to pharmacological blockade. Our novel 3D system represents a vascularized tumor model that is easy to image and quantify and is fully tunable in terms of input cells, perfusate, and matrices. We envision that this ccRCC-on-a-chip will be valuable for mechanistic studies, for studying tumor-vascular cell interactions, and for developing novel and personalized antitumor therapies.

4 March 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
CTConnor A. Tsuchida
Connor A. Tsuchida
KWKevin M. Wasko
Kevin M. Wasko
JHJennifer R. Hamilton
Jennifer R. Hamilton
JDJennifer A. Doudna
Jennifer A. Doudna
Cell-type-specific in vivo delivery of genome editing molecules is the next breakthrough that will drive biological discovery and transform the field of cell and gene therapy. Here, we discuss recent advances in the delivery of CRISPR-Cas genome editors either as preassembled ribonucleoproteins or encoded in mRNA. Both strategies avoid pitfalls of viral vector-mediated delivery and offer advantages including transient editor lifetime and potentially streamlined manufacturing capability that are already proving valuable for clinical use. We review current applications and future opportunities of these emerging delivery approaches that could make genome editing more efficacious and accessible in the future.

25 February 2022 in Molecular Cell
Verified
Journal Article
Closed access
CTConnor A. Tsuchida
Connor A. Tsuchida
SZShouyue Zhang
Shouyue Zhang
MDMohammad Saffari Doost
Mohammad Saffari Doost
YZYuqian Zhao
Yuqian Zhao
JWJia Wang
Jia Wang
JLJun-Jie Gogo Liu
Jun-Jie Gogo Liu

22 March 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
CTConnor A. Tsuchida
Connor A. Tsuchida
NBNadav Brandes
Nadav Brandes
RBRaymund Bueno
Raymund Bueno
MTMarena Trinidad
Marena Trinidad
TMThomas Mazumder
Thomas Mazumder
JDJennifer A. Doudna
Jennifer A. Doudna
Summary: CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced chromosome loss is a universal phenomenon and evaluate its clinical significance, we conducted a systematic analysis in primary human T cells. Arrayed and pooled CRISPR screens revealed that chromosome loss was generalizable across the genome and resulted in partial and entire loss of the chromosome, including in pre-clinical chimeric antigen receptor T cells. T cells with chromosome loss persisted for weeks in culture, implying the potential to interfere with clinical use. A modified cell manufacturing process, employed in our first-in-human clinical trial of Cas9-engineered T cells, 1 dramatically reduced chromosome loss while largely preserving genome editing efficacy. Expression of p53 correlated with protection from chromosome loss observed in this protocol, suggesting both a mechanism and strategy for T cell engineering that mitigates this genotoxicity in the clinic.